Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 282 articles:
HTML format
Text format



Single Articles


    June 2018
  1. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    PubMed     Text format     Abstract available


  2. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    PubMed     Text format     Abstract available


    May 2018
  3. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    PubMed     Text format     Abstract available


  4. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    PubMed     Text format     Abstract available


  5. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    PubMed     Text format     Abstract available


  6. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    PubMed     Text format     Abstract available


  7. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    PubMed     Text format     Abstract available


  8. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    PubMed     Text format     Abstract available


  9. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    PubMed     Text format     Abstract available


    April 2018
  10. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    PubMed     Text format     Abstract available


  11. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    PubMed     Text format     Abstract available


  12. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    PubMed     Text format     Abstract available


  13. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    PubMed     Text format     Abstract available


  14. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    PubMed     Text format     Abstract available


  15. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    PubMed     Text format     Abstract available


  16. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    PubMed     Text format     Abstract available


  17. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    PubMed     Text format     Abstract available


    March 2018
  18. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    PubMed     Text format     Abstract available


  19. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    PubMed     Text format     Abstract available


  20. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    PubMed     Text format     Abstract available


  21. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    PubMed     Text format     Abstract available


  22. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    PubMed     Text format     Abstract available


  23. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    PubMed     Text format     Abstract available


  24. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    PubMed     Text format     Abstract available


    February 2018
  25. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    PubMed     Text format     Abstract available


  26. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    PubMed     Text format     Abstract available


  27. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    PubMed     Text format     Abstract available


  28. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    PubMed     Text format     Abstract available


  29. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    PubMed     Text format     Abstract available


  30. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    PubMed     Text format     Abstract available


  31. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    PubMed     Text format     Abstract available


  32. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    PubMed     Text format     Abstract available


  33. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    PubMed     Text format     Abstract available


  34. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    PubMed     Text format     Abstract available


  35. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    PubMed     Text format     Abstract available


    January 2018
  36. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    PubMed     Text format     Abstract available


  37. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    PubMed     Text format     Abstract available


  38. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    PubMed     Text format     Abstract available


  39. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    PubMed     Text format     Abstract available


  40. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    PubMed     Text format     Abstract available


  41. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    PubMed     Text format     Abstract available


  42. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    PubMed     Text format     Abstract available


  43. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    PubMed     Text format     Abstract available


  44. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    PubMed     Text format     Abstract available


  45. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    PubMed     Text format     Abstract available


    December 2017
  46. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Text format     Abstract available


  47. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Text format     Abstract available


  48. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Text format     Abstract available


  49. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Text format     Abstract available


  50. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Text format     Abstract available


  51. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Text format     Abstract available


  52. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Text format     Abstract available


  53. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Text format     Abstract available


  54. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Text format     Abstract available


  55. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Text format     Abstract available


    November 2017
  56. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    PubMed     Text format     Abstract available


  57. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    PubMed     Text format     Abstract available


  58. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    PubMed     Text format     Abstract available


  59. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    PubMed     Text format     Abstract available


  60. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    PubMed     Text format     Abstract available


  61. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    PubMed     Text format     Abstract available


  62. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    PubMed     Text format     Abstract available


  63. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Text format     Abstract available


  64. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Text format     Abstract available


  65. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Text format     Abstract available


  66. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Text format     Abstract available


  67. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Text format     Abstract available


    October 2017
  68. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Text format     Abstract available


  69. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Text format     Abstract available


  70. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    PubMed     Text format     Abstract available


  71. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    PubMed     Text format     Abstract available


  72. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    PubMed     Text format     Abstract available


  73. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    PubMed     Text format     Abstract available


  74. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    PubMed     Text format     Abstract available


  75. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    PubMed     Text format     Abstract available


  76. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    PubMed     Text format     Abstract available


  77. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    PubMed     Text format     Abstract available


  78. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Text format     Abstract available


  79. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Text format     Abstract available


  80. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Text format     Abstract available


  81. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Text format     Abstract available


    August 2017
  82. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Text format     Abstract available


  83. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Text format     Abstract available


  84. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Text format     Abstract available


  85. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Text format     Abstract available


  86. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Text format     Abstract available


  87. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Text format     Abstract available


  88. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Text format     Abstract available


  89. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Text format     Abstract available


    July 2017
  90. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Text format     Abstract available


  91. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


  92. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available


  93. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Text format     Abstract available


  94. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Text format     Abstract available


  95. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Text format     Abstract available


    June 2017
  96. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Text format     Abstract available


  97. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Text format     Abstract available


  98. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Text format     Abstract available


  99. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Text format     Abstract available


  100. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Text format     Abstract available


  101. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Text format     Abstract available


  102. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Text format     Abstract available


  103. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Text format     Abstract available


  104. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Text format     Abstract available


    May 2017
  105. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Text format     Abstract available


  106. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Text format     Abstract available


  107. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Text format     Abstract available


  108. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Text format     Abstract available


  109. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Text format     Abstract available


  110. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Text format     Abstract available


  111. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Text format     Abstract available


  112. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Text format     Abstract available


  113. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Text format     Abstract available


    April 2017
  114. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Text format     Abstract available


  115. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Text format     Abstract available


  116. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Text format     Abstract available


    March 2017
  117. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Text format     Abstract available


  118. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Text format     Abstract available


  119. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Text format     Abstract available


  120. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    PubMed     Text format     Abstract available


  121. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    PubMed     Text format     Abstract available


  122. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    PubMed     Text format     Abstract available


  123. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    PubMed     Text format     Abstract available


  124. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    PubMed     Text format     Abstract available


  125. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    PubMed     Text format     Abstract available


  126. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    PubMed     Text format     Abstract available


  127. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    PubMed     Text format     Abstract available


    February 2017
  128. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    PubMed     Text format     Abstract available


  129. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    PubMed     Text format     Abstract available


  130. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    PubMed     Text format     Abstract available


  131. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    PubMed     Text format     Abstract available


  132. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    PubMed     Text format     Abstract available


    January 2017
  133. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    PubMed     Text format     Abstract available


  134. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    PubMed     Text format     Abstract available


  135. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    PubMed     Text format     Abstract available


  136. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    PubMed     Text format     Abstract available


  137. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    PubMed     Text format     Abstract available


  138. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Text format     Abstract available


    December 2016
  139. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    PubMed     Text format     Abstract available


  140. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    PubMed     Text format     Abstract available


  141. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    PubMed     Text format     Abstract available


  142. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    PubMed     Text format     Abstract available


  143. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    PubMed     Text format     Abstract available


  144. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    PubMed     Text format     Abstract available


  145. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    PubMed     Text format     Abstract available


  146. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    PubMed     Text format     Abstract available


  147. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    PubMed     Text format     Abstract available


  148. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    PubMed     Text format     Abstract available


  149. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    PubMed     Text format     Abstract available


  150. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    PubMed     Text format     Abstract available


  151. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    PubMed     Text format     Abstract available


  152. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    PubMed     Text format     Abstract available


  153. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    PubMed     Text format     Abstract available


  154. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    PubMed     Text format     Abstract available


  155. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    PubMed     Text format     Abstract available


  156. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    PubMed     Text format     Abstract available


  157. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    PubMed     Text format     Abstract available


  158. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    PubMed     Text format     Abstract available


  159. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    PubMed     Text format     Abstract available


  160. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    PubMed     Text format     Abstract available


    November 2016
  161. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    PubMed     Text format     Abstract available


  162. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    PubMed     Text format     Abstract available


  163. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    PubMed     Text format     Abstract available


  164. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    PubMed     Text format     Abstract available


  165. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    PubMed     Text format    


  166. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    PubMed     Text format     Abstract available


  167. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    PubMed     Text format     Abstract available


  168. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    PubMed     Text format     Abstract available


  169. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    PubMed     Text format    


    October 2016
  170. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    PubMed     Text format     Abstract available


  171. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    PubMed     Text format     Abstract available


  172. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    PubMed     Text format     Abstract available


  173. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    PubMed     Text format     Abstract available


  174. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    PubMed     Text format    


  175. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    PubMed     Text format     Abstract available


    September 2016
  176. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    PubMed     Text format     Abstract available


  177. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    PubMed     Text format     Abstract available


  178. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    PubMed     Text format     Abstract available


  179. EL-BENDARY M, Neamatallah M, Esmat G, Kamel E, et al
    Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study.
    J Viral Hepat. 2016 Sep 7. doi: 10.1111/jvh.12573.
    PubMed     Text format     Abstract available


    August 2016
  180. KEOSHKERIAN E, Hunter M, Cameron B, Nguyen N, et al
    Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.
    J Viral Hepat. 2016 Aug 25. doi: 10.1111/jvh.12576.
    PubMed     Text format     Abstract available


  181. PRABDIAL-SING N, Chirwa T, Thaver J, Smuts H, et al
    Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012.
    J Viral Hepat. 2016 Aug 21. doi: 10.1111/jvh.12571.
    PubMed     Text format     Abstract available


  182. ASPINALL EJ, Mitchell W, Schofield J, Cairns A, et al
    A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy.
    J Viral Hepat. 2016 Aug 11. doi: 10.1111/jvh.12580.
    PubMed     Text format     Abstract available


  183. KNOP V, Hoppe D, Welzel T, Vermehren J, et al
    Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    J Viral Hepat. 2016 Aug 8. doi: 10.1111/jvh.12578.
    PubMed     Text format     Abstract available


    July 2016
  184. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    PubMed     Text format     Abstract available


  185. WANG X, Gao F, Yuan G, Shi K, et al
    Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-alpha and ribavirin therapy.
    J Viral Hepat. 2016 Jul 24. doi: 10.1111/jvh.12574.
    PubMed     Text format     Abstract available


  186. SWANN RE, Mandalou P, Robinson MW, Ow MM, et al
    Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12568.
    PubMed     Text format     Abstract available


  187. WILLEMSE SB, Baak LC, Kuiken SD, van der Sluys Veer A, et al
    Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12567.
    PubMed     Text format     Abstract available


    June 2016
  188. SCHEURICH C, Schulze Zur Wiesch J, Kim AY, Lewis-Ximenez L, et al
    Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12560.
    PubMed     Text format    


  189. KAWAKAMI Y, Imamura M, Ikeda H, Suzuki M, et al
    Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12553.
    PubMed     Text format     Abstract available


  190. FULOP B, Mihm U, Rohde P, Buggisch P, et al
    Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
    J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562.
    PubMed     Text format     Abstract available


  191. YOUNOSSI ZM, Stepanova M, Sulkowski M, Naggie S, et al
    Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    J Viral Hepat. 2016 Jun 13. doi: 10.1111/jvh.12554.
    PubMed     Text format     Abstract available


  192. GANE E, Ben Ari Z, Mollison L, Zuckerman E, et al
    Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection.
    J Viral Hepat. 2016 Jun 12. doi: 10.1111/jvh.12552.
    PubMed     Text format     Abstract available


  193. DEBROY S, Hiraga N, Imamura M, Hayes CN, et al
    Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.
    PubMed     Text format     Abstract available


  194. GREBELY J, Litwin A, Dore GJ
    Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12550.
    PubMed     Text format    


    May 2016
  195. WEISSENBORN K, Tillmann HL
    HCV encephalopathy - an artefact due to medical care?
    J Viral Hepat. 2016 May 26. doi: 10.1111/jvh.12547.
    PubMed     Text format     Abstract available


  196. MIZOKAMI M, Dvory-Sobol H, Izumi N, Nishiguchi S, et al
    Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12549.
    PubMed     Text format     Abstract available


  197. TESHALE EH, Xing J, Moorman A, Holmberg SD, et al
    Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2013.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12548.
    PubMed     Text format     Abstract available


  198. LOWRY D, Burke T, Galvin Z, Ryan JD, et al
    Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12544.
    PubMed     Text format     Abstract available


  199. LIM EJ, Chin R, Nachbur U, Silke J, et al
    Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12541.
    PubMed     Text format     Abstract available


  200. DEUFFIC-BURBAN S, Obach D, Canva V, Pol S, et al
    Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    J Viral Hepat. 2016 May 4. doi: 10.1111/jvh.12546.
    PubMed     Text format     Abstract available


    April 2016
  201. RAZAVI H
    Making the case for looking beyond WHO estimates for the global burden of hepatitis C and B.
    J Viral Hepat. 2016 Apr 5. doi: 10.1111/jvh.12539.
    PubMed     Text format     Abstract available


  202. EL-SERAG HB, Kramer J, Duan Z, Kanwal F, et al
    Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    J Viral Hepat. 2016 Apr 3. doi: 10.1111/jvh.12533.
    PubMed     Text format     Abstract available


    March 2016
  203. LU M, Li J, Rupp LB, Holmberg SD, et al
    Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12538.
    PubMed     Text format     Abstract available


  204. BASNAYAKE SK, Easterbrook PJ
    Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12519.
    PubMed     Text format     Abstract available


  205. HARRIS RJ, Martin NK, Rand E, Mandal S, et al
    New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.
    J Viral Hepat. 2016 Mar 29. doi: 10.1111/jvh.12529.
    PubMed     Text format     Abstract available


  206. BUNCHORNTAVAKUL C, Reddy KR
    Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
    J Viral Hepat. 2016 Mar 28. doi: 10.1111/jvh.12534.
    PubMed     Text format     Abstract available


  207. GIUDICI F, Bertisch B, Negro F, Stirnimann G, et al
    Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12535.
    PubMed     Text format     Abstract available


  208. REN JP, Ying RS, Cheng YQ, Wang L, et al
    HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12537.
    PubMed     Text format     Abstract available


  209. MO H, Hedskog C, Svarovskaia E, Sun SC, et al
    Antiviral response and resistance analysis of treatment-naive HCV-infected patients receiving single and multiple doses of GS-9190.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12536.
    PubMed     Text format     Abstract available


  210. GRAY E, O'Leary A, Kieran JA, Fogarty E, et al
    Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    J Viral Hepat. 2016 Mar 21. doi: 10.1111/jvh.12532.
    PubMed     Text format     Abstract available


  211. PERUMALSWAMI PV, Patel N, Bichoupan K, Ku L, et al
    High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
    J Viral Hepat. 2016 Mar 17. doi: 10.1111/jvh.12530.
    PubMed     Text format     Abstract available


  212. YOUNOSSI ZM, Stepanova M, Henry L, Younossi I, et al
    Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.
    J Viral Hepat. 2016 Mar 14. doi: 10.1111/jvh.12528.
    PubMed     Text format     Abstract available


  213. RODRIGUEZ-TORRES M, Glass S, Hill J, Freilich B, et al
    GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
    J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527.
    PubMed     Text format     Abstract available


  214. ROQUE CUELLAR MC, Garcia-Lozano JR, Sanchez B, Praena-Fernandez JM, et al
    Lymphomagenesis-related gene expression in B cells from sustained virological responders with occult hepatitis C virus infection.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12526.
    PubMed     Text format     Abstract available


  215. ZAYED N, Gamal Eldeen H, Elmakhzangy H, Seif M, et al
    Therapeutic outcome of 6198 interferon-naive Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    J Viral Hepat. 2016 Mar 3. doi: 10.1111/jvh.12514.
    PubMed     Text format     Abstract available


    February 2016
  216. PEVELING-OBERHAG J, Arcaini L, Bankov K, Zeuzem S, et al
    The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12518.
    PubMed     Text format     Abstract available


  217. WOODE ME, Abu-Zaineh M, Perriens J, Renaud F, et al
    Potential market size and impact of hepatitis C treatment in low- and middle-income countries.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12516.
    PubMed     Text format     Abstract available


  218. HARRIS M, Ward E, Gore C
    Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12513.
    PubMed     Text format     Abstract available


  219. CHEN HH, Liu PF, Tsai HH, Yen RF, et al
    Re: Wangensteen et al. of a letter on 'Hepatitis C virus infection: a risk factor for Parkinson's disease.'
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12521.
    PubMed     Text format    


  220. WANGENSTEEN KJ, Krawitt EL, Hamill RW, Boyd JT, et al
    Hepatitis C virus infection: a risk factor for Parkinson's disease.
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12517.
    PubMed     Text format    


  221. SCHNIER C, Wild S, Kurdi Z, Povey C, et al
    Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 22. doi: 10.1111/jvh.12520.
    PubMed     Text format     Abstract available


  222. KONERMAN MA, Brown M, Zheng Y, Lok AS, et al
    Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12509.
    PubMed     Text format     Abstract available


  223. AHN SH, Lim YS, Lee KS, Paik SW, et al
    A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    J Viral Hepat. 2016 Feb 10. doi: 10.1111/jvh.12499.
    PubMed     Text format     Abstract available


  224. HAWKS L, Norton BL, Cunningham CO, Fox AD, et al
    The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.
    J Viral Hepat. 2016 Feb 9. doi: 10.1111/jvh.12512.
    PubMed     Text format     Abstract available


  225. MEISSNER EG, Kohli A, Virtaneva K, Sturdevant D, et al
    Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12510.
    PubMed     Text format     Abstract available


  226. FALADE-NWULIA O, Mehta SH, Lasola J, Latkin C, et al
    Public health clinic-based hepatitis C testing and linkage to care in baltimore.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12507.
    PubMed     Text format     Abstract available


  227. YOUNOSSI ZM, Bacon BR, Dieterich DT, Flamm SL, et al
    Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12506.
    PubMed     Text format     Abstract available


  228. MINA MM, Cameron B, Luciani F, Vollmer-Conna U, et al
    Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12511.
    PubMed     Text format     Abstract available


  229. BROERING R, Trippler M, Werner M, Real CI, et al
    Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12508.
    PubMed     Text format     Abstract available


  230. POITEAU L, Soulier A, Rosa I, Roudot-Thoraval F, et al
    Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12501.
    PubMed     Text format     Abstract available


  231. PAPATHEODORIDIS G, Thomas HC, Golna C, Bernardi M, et al
    Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
    J Viral Hepat. 2016;23 Suppl 1:1-12.
    PubMed     Text format     Abstract available


    January 2016
  232. STUBBS A, Naylor P, Ravindran K, Benjaram S, et al
    Racial diversity in mortality and morbidity in urban patients with hepatitis C.
    J Viral Hepat. 2016 Jan 28. doi: 10.1111/jvh.12504.
    PubMed     Text format     Abstract available


  233. VIDAL LL, Soares MA, Santos AF
    NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects.
    J Viral Hepat. 2016 Jan 18. doi: 10.1111/jvh.12503.
    PubMed     Text format     Abstract available


  234. PFLUGRAD H, Meyer GJ, Dirks M, Raab P, et al
    Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction.
    J Viral Hepat. 2016 Jan 15. doi: 10.1111/jvh.12496.
    PubMed     Text format     Abstract available


  235. ORTEGA-PRIETO AM, Dorner M
    The expanding toolbox for hepatitis C virus research.
    J Viral Hepat. 2016 Jan 13. doi: 10.1111/jvh.12500.
    PubMed     Text format     Abstract available


    December 2015
  236. DUARTE-ROJO A, Fischer SE, Adeyi O, Zita D, et al
    Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
    J Viral Hepat. 2015 Dec 29. doi: 10.1111/jvh.12494.
    PubMed     Text format     Abstract available


  237. BURCHILL MA, Golden-Mason L, Wind-Rotolo M, Rosen HR, et al
    Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
    J Viral Hepat. 2015;22:983-91.
    PubMed     Text format     Abstract available


  238. ALFALEH FZ, Nugrahini N, Maticic M, Tolmane I, et al
    Strategies to manage hepatitis C virus infection disease burden - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:42-65.
    PubMed     Text format     Abstract available


  239. SIBLEY A, Han KH, Abourached A, Lesmana LA, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:21-41.
    PubMed     Text format     Abstract available


  240. LIAKINA V, Hamid S, Tanaka J, Olafsson S, et al
    Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.
    J Viral Hepat. 2015;22 Suppl 4:4-20.
    PubMed     Text format     Abstract available


  241. AGHEMO A, Dore GJ, Hatzakis A, Wedemeyer H, et al
    Estimating HCV disease burden - volume 3 (editorial).
    J Viral Hepat. 2015;22 Suppl 4:1-3.
    PubMed     Text format    


  242. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    PubMed     Text format     Abstract available


    November 2015
  243. YOUNG KL, Huang W, Horsburgh CR, Linas BP, et al
    Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12489.
    PubMed     Text format     Abstract available


  244. FOSTER GR, Ferenci P, Asselah T, Mantry P, et al
    Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12485.
    PubMed     Text format     Abstract available


  245. DULTZ G, Gerber L, Zeuzem S, Sarrazin C, et al
    The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
    J Viral Hepat. 2015 Nov 10. doi: 10.1111/jvh.12488.
    PubMed     Text format     Abstract available


  246. GONZALES CA, Bacchetti P, Khalili M
    Impact of gender and menopausal status on metabolic parameters in chronic hepatitis C infection.
    J Viral Hepat. 2015 Nov 10. doi: 10.1111/jvh.12487.
    PubMed     Text format     Abstract available


  247. CHANG ML, Huang YH, Cheng JC, Yeh CT, et al
    Interaction between hepatic membrane type 1 matrix metalloproteinase and acireductone dioxygenase 1 regulates hepatitis C virus infection.
    J Viral Hepat. 2015 Nov 5. doi: 10.1111/jvh.12486.
    PubMed     Text format     Abstract available


    October 2015
  248. PADAM P, Clark S, Irving W, Gellissen R, et al
    Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.
    J Viral Hepat. 2015 Oct 29. doi: 10.1111/jvh.12484.
    PubMed     Text format     Abstract available


  249. YOUNOSSI Z, Brown A, Buti M, Faiguoli S, et al
    Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
    J Viral Hepat. 2015 Oct 20. doi: 10.1111/jvh.12483.
    PubMed     Text format     Abstract available


  250. RIOU J, Ait Ahmed M, Blake A, Vozlinsky S, et al
    Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis.
    J Viral Hepat. 2015 Oct 19. doi: 10.1111/jvh.12481.
    PubMed     Text format     Abstract available


  251. RAJALAKSHMY AR, Malathi J, Madhavan HN
    Serum-derived hepatitis C virus 1a infection of human astrocyte cell line SVG.
    J Viral Hepat. 2015 Oct 15. doi: 10.1111/jvh.12480.
    PubMed     Text format     Abstract available


  252. WARING JF, Dumas EO, Abel S, Coakley E, et al
    Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
    J Viral Hepat. 2015 Oct 5. doi: 10.1111/jvh.12470.
    PubMed     Text format     Abstract available


    September 2015
  253. STAHMEYER JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, et al
    Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    J Viral Hepat. 2015 Sep 28. doi: 10.1111/jvh.12471.
    PubMed     Text format     Abstract available


  254. CARMO RF, Aroucha D, Vasconcelos LR, Pereira LM, et al
    Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV.
    J Viral Hepat. 2015 Sep 24. doi: 10.1111/jvh.12472.
    PubMed     Text format     Abstract available


  255. FERNANDEZ-MONTERO JV, Barreiro P, de Mendoza C, Labarga P, et al
    Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients.
    J Viral Hepat. 2015 Sep 21. doi: 10.1111/jvh.12447.
    PubMed     Text format     Abstract available


  256. LAGGING M, Brown A, Mantry PS, Ramji A, et al
    Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    J Viral Hepat. 2015 Sep 10. doi: 10.1111/jvh.12464.
    PubMed     Text format     Abstract available


    August 2015
  257. WOZNIAK MA, Lugo Iparraguirre LM, Dirks M, Deb-Chatterji M, et al
    Apolipoprotein E-epsilon4 deficiency and cognitive function in hepatitis C virus-infected patients.
    J Viral Hepat. 2015 Aug 26. doi: 10.1111/jvh.12443.
    PubMed     Text format     Abstract available


  258. TRELOAR C, Rance J, Bryant J, Fraser S, et al
    Understanding decisions made about hepatitis C treatment by couples who inject drugs.
    J Viral Hepat. 2015 Aug 25. doi: 10.1111/jvh.12451.
    PubMed     Text format     Abstract available


  259. YIN P, Zhang L
    Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12446.
    PubMed     Text format     Abstract available


  260. YOUNOSSI ZM, Stepanova M, Saab S, Ahmed A, et al
    The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449.
    PubMed     Text format     Abstract available


  261. YOUNOSSI ZM, Elsheikh E, Stepanova M, Gerber L, et al
    Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    J Viral Hepat. 2015 Aug 17. doi: 10.1111/jvh.12448.
    PubMed     Text format     Abstract available


  262. PHO MT, Jensen DM, Meltzer DO, Kim AY, et al
    Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
    J Viral Hepat. 2015;22:630-638.
    PubMed     Text format     Abstract available


  263. CRAXI L, Camma C, Craxi A
    HCV: the best cure possible or the best possible cure?
    J Viral Hepat. 2015;22:627-629.
    PubMed     Text format     Abstract available


  264. ATHANASAKIS K, Petrakis I, Kyriopoulos J
    'HepConomics': cost-effective, indeed, but how can we pay for it?
    J Viral Hepat. 2015;22:682.
    PubMed     Text format    


    July 2015
  265. NADKARNI GN, Patel A, Simoes PK, Yacoub R, et al
    Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis.
    J Viral Hepat. 2015 Jul 20. doi: 10.1111/jvh.12437.
    PubMed     Text format     Abstract available


  266. LAWITZ E, Freilich B, Link J, German P, et al
    A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
    J Viral Hepat. 2015 Jul 16. doi: 10.1111/jvh.12435.
    PubMed     Text format     Abstract available


    June 2015
  267. SARKAR M, Aouzierat B, Bacchetti P, Prokunina-Ollson L, et al
    Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women.
    J Viral Hepat. 2015 Jun 26. doi: 10.1111/jvh.12431.
    PubMed     Text format     Abstract available


  268. CHEN W, Krahn M
    Disease burden of chronic hepatitis C among immigrants in Canada.
    J Viral Hepat. 2015 Jun 25. doi: 10.1111/jvh.12432.
    PubMed     Text format     Abstract available


  269. DOYLE JS, Deterding K, Grebely J, Wedemeyer H, et al
    Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
    J Viral Hepat. 2015 Jun 22. doi: 10.1111/jvh.12429.
    PubMed     Text format     Abstract available


  270. GUTIERREZ JA, Lawitz EJ, Poordad F
    Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
    J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12422.
    PubMed     Text format     Abstract available


  271. HUANG QT, Huang Q, Zhong M, Wei SS, et al
    Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies.
    J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12430.
    PubMed     Text format     Abstract available


  272. OGAWA E, Furusyo N, Dohmen K, Kajiwara E, et al
    Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    J Viral Hepat. 2015 Jun 15. doi: 10.1111/jvh.12427.
    PubMed     Text format     Abstract available


    May 2015
  273. SETHI N, Tapper EB, Vong A, Sethi S, et al
    Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    J Viral Hepat. 2015 May 25. doi: 10.1111/jvh.12421.
    PubMed     Text format     Abstract available


  274. ALAVI M, Micallef M, Fortier E, Dunlop AJ, et al
    Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
    J Viral Hepat. 2015 May 21. doi: 10.1111/jvh.12415.
    PubMed     Text format     Abstract available


  275. BUTI M, Llaneras J, Riveiro-Barciela M, Esteban R, et al
    Therapy for hepatitis C genotype 3: moving forward.
    J Viral Hepat. 2015 May 13. doi: 10.1111/jvh.12419.
    PubMed     Text format     Abstract available


    March 2015
  276. WIKTOR SZ
    Where next for hepatitis B and C surveillance?
    J Viral Hepat. 2015 Mar 6. doi: 10.1111/jvh.12400.
    PubMed     Text format     Abstract available


    February 2015
  277. AKAMATSU S, Hayes CN, Tsuge M, Murakami E, et al
    Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
    J Viral Hepat. 2015;22:166-74.
    PubMed     Text format     Abstract available


    January 2015
  278. LEJNINE S, Marton MJ, Wang IM, Howell BJ, et al
    Gene expression analysis in serial liver fine needle aspirates.
    J Viral Hepat. 2015;22:64-76.
    PubMed     Text format     Abstract available


    October 2014
  279. MENNA P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, et al
    Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.
    J Viral Hepat. 2014;21:e136-7.
    PubMed     Text format    


    September 2014
  280. PAPATHEODORIDIS G, Sypsa V, Kantzanou M, Nikolakopoulos I, et al
    Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey.
    J Viral Hepat. 2014 Sep 11. doi: 10.1111/jvh.12314.
    PubMed     Text format     Abstract available


    June 2014
  281. VAN DER LAAN LJ, de Ruiter PE, van Gils IM, Fieten H, et al
    Canine hepacivirus and idiopathic hepatitis in dogs from a Dutch cohort.
    J Viral Hepat. 2014 Jun 5. doi: 10.1111/jvh.12268.
    PubMed     Text format     Abstract available


    January 2014
  282. LI J, Gordon SC, Rupp LB, Zhang T, et al
    The validity of serum markers for fibrosis staging in chronic hepatitis B and C.
    J Viral Hepat. 2014 Jan 29. doi: 10.1111/jvh.12224.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: